Topical tofacitinib for the management of lymphocytic-variant hypereosinophilic syndrome with cutaneous involvement.

Said, Jordan T; Elman, Scott A; Tawa, Marianne; Fisher, David C; Merola, Joseph F; Kupper, Thomas S

Said, Jordan T; Elman, Scott A; Tawa, Marianne; Fisher, David C; Merola, Joseph F; Kupper, Thomas S.

Afiliación

Said JT; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Elman SA; Harvard Medical School, Boston, Massachusetts, USA.
Tawa M; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Fisher DC; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Merola JF; Harvard Medical School, Boston, Massachusetts, USA.
Kupper TS; Medical Oncology/Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Dermatol Ther ; 35(7): e15518, 2022 07.

Article en En | MEDLINE | ID: mdl-35426208

Asunto(s)

Síndrome Hipereosinofílico; Humanos; Síndrome Hipereosinofílico/diagnóstico; Síndrome Hipereosinofílico/tratamiento farmacológico; Piperidinas; Pirimidinas

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome Hipereosinofílico Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Dermatol Ther Asunto de la revista: DERMATOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google